{"url":"https://lda.senate.gov/api/v1/filings/cb88f4a9-5c0b-42c3-b4ce-e346c7db89bf/","filing_uuid":"cb88f4a9-5c0b-42c3-b4ce-e346c7db89bf","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2024,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/cb88f4a9-5c0b-42c3-b4ce-e346c7db89bf/print/","filing_document_content_type":"text/html","income":"80000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Darren Willcox","dt_posted":"2025-01-21T12:05:30-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1455 Pennsylvania Avenue, NW","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":400605842,"url":"https://lda.senate.gov/api/v1/registrants/400605842/","house_registrant_id":null,"name":"W STRATEGIES, LLC","description":"Government Affairs Consulting Firm.","address_1":"1455 Pennsylvania Avenue, NW","address_2":"Suite 400","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"DARREN WILLCOX","contact_telephone":"+1 202-494-6268","dt_updated":"2026-01-30T17:48:20.361860-05:00"},"client":{"id":193505,"url":"https://lda.senate.gov/api/v1/clients/193505/","client_id":214,"name":"ASTRAZENECA PHARMACEUTICALS LP","general_description":"Biopharmaceutical Company.","client_government_entity":false,"client_self_select":null,"state":"DE","state_display":"Delaware","country":"US","country_display":"United States of America","ppb_state":"DE","ppb_state_display":"Delaware","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2014-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.5539 - ORPHAN Cures Act. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":51473,"prefix":null,"prefix_display":null,"first_name":"DARREN","nickname":null,"middle_name":null,"last_name":"WILLCOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to about insurance coverage of specialty treatments.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":51473,"prefix":null,"prefix_display":null,"first_name":"DARREN","nickname":null,"middle_name":null,"last_name":"WILLCOX","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}